The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
Abstract
BACKGROUND: Proton pump inhibitors such as omeprazole and lansoprazole are mainly metabolized by CYP2C19 in the liver. The therapeutic effects of proton pump inhibitors are assumed to depend on CYP2C19 genotype status. OBJECTIVE: We investigated whether CYP2C19 genotype status was related to eradication rates of H pylori by triple proton pump inhibitor-clarithromycin-amoxicillin (INN, amoxicilline) therapy and attempted to establish a strategy for treatment after failure to eradicate H pylori. METHODS: A total of 261 patients infected with H pylori completed initial treatment with 20 mg of omeprazole or 30 mg of lansoprazole twice a day, 200 mg of clarithromycin three times a day, and 500 mg of amoxicillin three times a day for 1 week. CYP2C19 genotypes of patients were determined with polymerase chain reaction-restriction fragment length polymorphism analysis. Patients without eradication after initial treatment were retreated with 30 mg of lansoprazole four times daily and 500 mg of amoxicillin four times daily for 2 weeks. RESULTS: Eradication rates for H pylori were 72.7% (95% confidence interval, 64.4%-81.8%), 92.1% (confidence interval, 86.4%-97.3%), and 97.8% (confidence interval, 88.5%-99.9%) in the homozygous extensive, heterozygous extensive, and poor metabolizer groups, respectively. Thirty-four of 35 patients without eradication had an extensive metabolizer genotype of CYP2C19. Nineteen of those patients were infected with clarithromycin-resistant strains of H pylori. However, there were no amoxicillin-resistant strains of H pylori. Re-treatment of H pylori infection with dual high-dose lansoprazole-amoxicillin therapy succeeded in 30 of 31 patients with extensive metabolizer genotype of CYP2C19. CONCLUSION: The majority of patients without initial eradication of H pylori had an extensive metabolizer CYP2C19 genotype but were successfully re-treated with high doses of lansoprazole and an antibiotic to which H pylori was sensitive, such as amoxicillin, even when the patients were infected with clarithromycin-resistant strains of H pylori.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wotherspoon, A. C., Diss, T. C., Pan, L., Isaacson, P. G., Doglioni, C., Moschini, A., & de Boni, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)91409-f · Cited by 2,118
PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI
Marshall, B., Warren, J. R., Blincow, E., Phillips, M., Goodwin, C. S., Murray, R., Blackbourn, S., Waters, T., & Sanderson, C. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90929-4 · Cited by 1,037
Erythromycin resistance by ribosome modification
Weisblum, B. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.577 · Cited by 1,008
De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., & Goldstein, J. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09788-3 · Cited by 752
Campylobacter pylori and Peptic Ulcer Disease
Graham, D. Y. (1989) · Gastroenterology · doi:10.1016/s0016-5085(89)80057-5 · Cited by 731
Lind, T., van Zanten, S. V., Unge, P., Spiller, R., Bayerdörffer, E., O'Morain, C., Bardhan, K. D., Bradette, M., Chiba, N., Wrangstadh, M., et al. (1996) · Helicobacter · doi:10.1111/j.1523-5378.1996.tb00027.x · Cited by 573
Uemura, N., Mukai, T., Okamoto, S., Yamaguchi, S., Mashiba, H., Taniyama, K., Sasaki, N., Haruma, K., Sumii, K., & Kajiyama, G. (1997) · PubMed · Cited by 546
Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori
Versalovic, J., Shortridge, D., Kibler, K., Griffy, M. V., Beyer, J., Flamm, R. K., Tanaka, S. K., Graham, D. Y., & Go, M. F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.477 · Cited by 501
Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., & Branch, R. A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.194 · Cited by 452
Lind, T., Mégraud, F., Unge, P., Bayerdörffer, E., O'Morain, C., Spiller, R., van Zanten, S. V., Bardhan, K. D., Hellblom, M., Wrangstadh, M., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70119-8 · Cited by 434
The Treatment of Helicobacter pylori Infection in the Management of Peptic Ulcer Disease
Walsh, J. H., & Peterson, W. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331508 · Cited by 383
Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T., & Kaneko, E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00006 · Cited by 335
Self-citationAndersson, T. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631010-00002 · Cited by 326
Sackmann, M., Morgner, A., Rudolph, B., Neubauer, A., Thiede, C., Schulz, H., Kraemer, W., Boersch, G., Rohde, P., Seifert, E., et al. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322502 · Cited by 300
Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population*
Kubota, T., Chiba, K., & Ishizaki, T. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90214-3 · Cited by 288
genotype status and effect of omeprazole on intragastric pH in humans
FURUTA, T., OHASHI, K., KOSUGE, K., ZHAO, X., TAKASHIMA, M., KIMURA, M., NISHIMOTO, M., HANAI, H., KANEKO, E., & ISHIZAKI, T. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70075-5 · Cited by 272
Self-citationMedical Treatment of Peptic Ulcer Disease: Practice Guidelines
Soll, A. H. (1996) · JAMA · doi:10.1001/jama.1996.03530320046033 · Cited by 259
Resistance of Helicobacter pylori to antibiotics
MÉGRAUD, F. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.11.s1.11.x · Cited by 242
Peterson, W. L., Graham, D. Y., Marshall, B. J., Blaser, M. J., Genta, R. M., Klein, P., Stratton, C. W., Drnec, J., Prokocimer, P., & Siepman, N. Y. (1993) · PubMed · Cited by 229
The life and death of helicobacter pylori
Scott, D., Weeks, D., Melchers, K., & Sachs, G. (1998) · Gut · doi:10.1136/gut.43.2008.s56 · Cited by 222
Goddard, A., Jessa, M., Barrett, D., Shaw, P., Idstrom, J., Cederberg, C., & Spiller, R. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8690200 · Cited by 218
Horai, Y., Nakano, M., Ishizaki, T., Ishikawa, K., Zhou, H.-H., Zhou, B.-J., Liao, C.-L., & Zhang, L.-M. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.126 · Cited by 217
Goodwin, C. S., Mendall, M. M., & Northfield, T. C. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07023-7 · Cited by 212
Bayerdörffer, E., Miehlke, S., Mannes, G. A., Sommer, A., Höchter, W., Weingart, J., Heldwein, W., Klann, H., Simon, T., Schmitt, W., et al. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90689-4 · Cited by 211
Adamek, R. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(97)00110-x · Cited by 202
Chang, M., Tybring, G., Dahl, M., Gotharson, E., Sagar, M., Seensalu, R., & Bertilsson, L. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04488.x · Cited by 184
Xie, H.-G., Stein, C. M., Kim, R. B., Wilkinson, G. R., Flockhart, D. A., & Wood, A. J. J. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00001 · Cited by 181
Effect of varying pH on the susceptibility ofCampylobacter pylori to antimicrobial agents
Grayson, M. L., Eliopoulos, G. M., Ferraro, M. J., & Moellering, R. C. (1989) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/bf01963775 · Cited by 166
The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study*
Balian, J. D., Sukhova, N., Harris, J. W., Hewett, J., Pickle, L. W., Goldstein, J. A., Woosley, R. L., & Flockhart, D. A. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90229-5 · Cited by 151
Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.
Andersson, T., Miners, J. O., Veronese, M., & Birkett, D. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04310.x · Cited by 146
Ad, R., Roberts, E. M., Dj, M., Yao, Y., & Ouellet, D. (1997) · PubMed · Cited by 139
Yasuda, S., Horai, Y., Tomono, Y., Nakai, H., Yamato, C., Manabe, K., Kobayashi, K., Chiba, K., & Ishizaki, T. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90192-2 · Cited by 137
Evaluation of a new selective medium forCampylobacter pylori
Dent, J. C., & McNulty, C. A. M. (1988) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01962615 · Cited by 128
Furuta, T., Ohashi, K., Kobayashi, K., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70034-2 · Cited by 121
Self-citationMarais, A., Monteiro, L., Occhialini, A., Pina, M., Lamouliatte, H., & Mégraud, F. (1999) · Gut · doi:10.1136/gut.44.4.463 · Cited by 120
Ieiri, I., Kubota, T., Urae, A., Kimura, M., Wada, Y., Mamiya, K., Yoshioka, S., Irie, S., Amamoto, T., Nakamura, K., et al. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90004-1 · Cited by 112
Mechanism of clarithromycin resistance in clinical isolates ofHelicobacter pylori
Debets-Ossenkopp, Y. J., Sparrius, M., Kusters, J. G., et al. (1996) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1996.tb08404.x · Cited by 108
Sohn, D., Kwon, J., Kim, H.-K., & Ishizaki, T. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90137-5 · Cited by 89
Review ofHelicobacter pyloriEradication Regimens
Unge, P. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609094541 · Cited by 80
Effect ofHelicobacter pyloriInfection on Gastric Juice pH
Furuta, T. (1998) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529850170973 · Cited by 79
Self-citationMaeda, S., Yoshida, H., Ogura, K., Kanai, F., Shiratori, Y., & Omata, M. (1998) · Gut · doi:10.1136/gut.43.3.317 · Cited by 60
Furuta, T. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.106826 · Cited by 39
Self-citationGotoh, A., Kawakami, Y., Akahane, T., Akamatsu, T., Shimizu, T., Kiyosawa, K., & Katsuyama, T. (1997) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1997.tb01166.x · Cited by 34
Cited by
Pathogenesis of Helicobacter pylori Infection
Kusters, J. G., van Vliet, A. H. M., & Kuipers, E. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00054-05 · Cited by 2,526
Drug Metabolism and Variability among Patients in Drug Response
Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Metadata
- Authors
- Furuta, T.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2001-03
- Volume
- 69
- Issue
- 3
- Pages
- 158-168
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2077642428
- Cited by
- 254
- References
- 43
- FWCI
- 14.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.